-
Penpulimab Monoclonal Antibody (PD-1) Obtains Marketing Approval in China
prnasia
August 06, 2021
Akeso, Inc. announced that the anti PD-1 monoclonal antibody drug Penpulimab monoclonal antibody injection co-developed by the Company with Sino Biopharmaceutical Limited, has obtained marketing approval by the National Medical Products Administration ...
-
Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI321 (Anti-PD-1/TIGIT Bispecific Antibody) in Patients with Advanced Malignant Tumors
prnasia
July 26, 2021
Innovent Biologics, Inc. today announced that the first patient has been dosed in a Phase 1 study of IBI321, an anti-PD-1/TIGIT bispecific antibody.
-
Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI319 (Anti-PD-1/CD137 Bispecific Antibody) in Patients with Advanced Malignant Tumors
prnasia
July 16, 2021
Innovent Biologics, Inc. announced that the first patient has been dosed in a Phase 1a/1b study of IBI319, an anti-PD-1/CD137 bispecific antibody.
-
Innovent and Laekna Therapeutics Enter a Partnership Agreement to Co-Develop Combination Therapy of Sintilimab and Afuresertib in Clinical Studies in China
prnasia
July 06, 2021
Innovent and Laekna today jointly announced they have entered into a collaboration agreement to evaluate the combination of Innovent's PD-1 inhibitor sintilimab and Laekna's pan-AKT kinase inhibitor afuresertib.
-
ImmVira completed the first dosing for Phase II of MVR-T3011 (intratumoral injection) in the U.S. and China
prnasia
June 15, 2021
ImmVira announced that in the Phase II Clinical Trials of its leading oncolytic virus product, MVR-T3011* as intratumoral administration (MVR-T3011 IT), ImmVira has completed the first dosing in both China and the U.S. on May 28 2021 and June 11 2021 ...
-
Tislelizumab reduces risk of death by 30 percent in oesophageal cancer trial
europeanpharmaceuticalreview
June 08, 2021
In a Phase III trial, Novartis’ investigational checkpoint inhibitor tislelizumab improved overall survival in patients with oesophageal squamous cell carcinoma.
-
Akeso's Penpulimab Monoclonal Antibody Submitted BLA in the United States
prnasia
May 25, 2021
On May 24, 2021, Akeso, Inc. announced that Penpulimab, an PD-1 monoclonal antibody drug co-developed by the Company with Sino Biopharmaceutical Limited, has submitted a Biologics License Application to the Food and Drug Administration of the ...
-
Agenus Submits Balstilimab Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
americanpharmaceuticalreview
April 20, 2021
Agenus Inc., an immuno-oncology company with an extensive pipeline of agents which includes checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, announced the submission of a ...
-
Harbour BioMed Announces Dosing of First Patient in Phase I Clinical Study of its Next-Generation Anti-CTLA-4 Antibody in China
prnasia
March 22, 2021
Harbour BioMed (HBM) today announced the dosing of the first patient in its open Phase I clinical study of HBM4003 for Chinese patients suffering from advanced melanoma and other solid tumors (study No. 4003.2).
-
Libtayo® improves overall survival in advanced cervical cancer patients
europeanpharmaceuticalreview
March 16, 2021
A Phase III trial evaluating Libtayo® (cemiplimab) monotherapy in advanced cervical cancer has been stopped early due to a positive result on overall survival.